Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader | SUPN Stock NewsStockTitan·Nov 2, 2026 at 06:18 AMINDV0.00%SUPN+1.78%
SUPN: Record Q3 revenue and growth-product momentum; FY guidance raised ahead of merger closeQuartr·Oct 29, 2026 at 08:12 PMINDV0.00%SUPN+1.78%
Indivior Non-GAAP EPS of $1.32 beats by $0.19, revenue of $356M beats by $26.65Mbusinessinsider·Oct 29, 2026 at 11:15 AMINDV0.00%INDV
MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600 | ABR Stock NewsStockTitan·Oct 22, 2026 at 02:08 PMABR-1.54%HURN+1.47%
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate UpdateGlobeNewswire·Sep 28, 2026 at 05:00 AMADXN-23.25%INDV0.00%
Addex Therapeutics shares are trading higher after the company announced it regained full global rights to all GABAB positive allosteric modulator assets discovered under its research collaboration with Indivior UK.benzinga_article·Sep 25, 2026 at 12:28 PMADXN-23.25%INDV0.00%
Indivior Q2 2026 Earnings Call: Complete Transcriptbenzinga_article·Aug 17, 2026 at 09:19 AMSUPN+1.78%INDV0.00%
Key deals this week: Bending Spoons, Advanced Micro Devices, Visa, Prologis, and morebusinessinsider·Aug 9, 2026 at 02:59 PMATKR0.00%LNTH+0.34%
Supernus and Indivior merge to create scaled, CNS-focused entityPharmaceutical Technology·Aug 4, 2026 at 10:57 AMSUPN+1.78%INDV0.00%
Supernus, Indivior agree all-stock merger, combined firm to trade as Supernus on NasdaqPUBT·Aug 3, 2026 at 10:31 AMSUPN+1.78%INDV0.00%
